NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Dabrafenib for treating unresectable, advanced or metastatic BRAFV600 mutation-positive melanoma [ID605]

Please sign and return to:

[TAA], Technology Appraisal Administrator
Email: [TACommXXXX@nice.org.uk]
Fax: +44 (0)20 xxxx xxxx
Post: NICE, 10 Spring Gardens, London, SW1A 2BU

I confirm that:

- I agree with the content of the statement submitted by **NCRI/RCP/RCR/ACP/JCCO which I was responsible for compiling** and consequently I will not be submitting an additional personal statement.

Name: .....Dr Pippa Corrie

Signed: .....

Date: 16 06 14